Agency Forms Undergoing Paperwork Reduction Act Review, 90703-90705 [2024-26780]
Download as PDF
<![CDATA[
90703
Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
responses per
respondent
Annual .....................................................
One-time Addition of Diseases and Data
Elements.
2
2
1
1
75
3
150
6
.................................................................
....................
........................
....................
18,414
Form name
Cities .......................................................
Cities .......................................................
Total .................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–26778 Filed 11–15–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–25–24HQ]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Division of
Diabetes Translation Programmatic &
Participant User Experience Data
Collection (DDTDC)’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on July 26,
2024 to obtain comments from the
public and affected agencies. CDC
received zero comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
VerDate Sep<11>2014
17:17 Nov 15, 2024
Jkt 265001
Average
burden per
response
(in hours)
Number of
respondents
Type of respondent
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Division of Diabetes Translation
Programmatic & Participant User
Experience Data Collection (DDTDC)—
New—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Division of Diabetes Translation
(DDT) plays a crucial role in helping
prevent Type 2 diabetes, reducing
diabetes complications and disability,
and reducing diabetes-related
disparities across the United States.
DDT accomplishes this by providing
education, training, technical assistance
(TA), and engaging in communication/
marketing activities for various key
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Total
burden
(in hours)
audiences. These customers include
national, state, and local partners,
grantees, providers (e.g., lifestyle
coaches, diabetes educators, healthcare
providers, health/medical and
community-based organizations), people
with prediabetes, diabetes and their
family, friends, and caregivers, and
other consumers of DDT products and
programs.
For DDT to be able to efficiently and
effectively do this work and fulfill its
mission, it needs to be able to collect
information and feedback from intended
audiences in a timely manner and with
enough frequency to ensure DDT can
deliver clear, effective, efficient, and
appropriate customer service. This
includes, for instance, collecting data on
key audiences’ needs and on the reach,
uptake, use, customer experience and
satisfaction with DDT’s services,
products, and related programs,
including its education, training, TA
and communications services and
products.
However, in the interest of timely
provision of services, DDT often forgoes
the important step of getting input from
its key audiences on the clarity,
efficiency, effectiveness, and
appropriateness of the services and
resources it develops and provides for
them. Skipping this information
collection step, or doing so with less
frequency, avoids the delay involved in
the standard OMB review process, but
increases the risk of DDT wasting both
time and money developing and
providing education, training, TA, and
communication/marketing that will not
achieve the intended objectives and will
be unclear, irrelevant, or not fully meet
the needs of DDT’s audiences. It can
also have other unintended
consequences, such as jeopardizing the
credibility of Federal health officials.
The Division of Diabetes Translation
Programmatic & Participant User
Experience Data Collection (DDTDC)
will enable DDT to collect the
information they require in a timely
manner to:
• Provide clear, effective, efficient,
appropriate, and timely education,
communication, training, and technical
E:\FR\FM\18NON1.SGM
18NON1
90704
Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices
assistance to key audiences and other
interested groups, including consumer
audiences (e.g., people with prediabetes,
diabetes, and their family, friends, and
caregivers), providers (e.g., lifestyle
coaches, diabetes care and education
specialists, healthcare and other
providers, health/medical and
community-based organizations); and
partners (national, state, and local
partners).
• Ensure quality and prevent
duplication in the development and
dissemination of prevention and health
information and program activities by
DDT to consumers, providers, and state
and local partners.
• Conduct exploratory/formative
assessments to inform DDT’s
development of education,
communication/marketing, training, and
programmatic materials, tools, and
resources to support and improve the
prevention and management of diabetes.
For example, identifying key audiences’
knowledge, attitudes, behaviors,
motivators, and information needs.
• Assess the impact of programs,
messages, educational and training
materials among recipients and
determine to what extent they meet
relevant service-related DDT objectives
and goals.
The following are examples of the
areas of focus that the data collection
activities under this generic information
collection mechanism may include:
• Reach, uptake, use, customer
experience, and satisfaction with the
CDC-recognized lifestyle change
programs for type 2 diabetes prevention,
as well as related outcomes (e.g.,
participant retention and recruitment
rates).
• Satisfaction with CDC-recognized
lifestyle change programs toolkits, such
as the Personal Success Tool and
Champion toolkits.
• Reach, uptake, use, customer
experience, and satisfaction with
diabetes education, type 2 prevention,
and diabetes management innovations
(such as the Diabetes Self-Management
Education and Support services
promotion initiative) and related shortterm effects on knowledge, awareness,
practices (such as information seeking),
and outcomes (such as enrollment of
people with diabetes or prediabetes).
• Reach, uptake, satisfaction,
customer experience, and short-term
outcomes of CDC’s training and
technical assistance resources (such as a
webinar or online toolkit).
• Needs assessments for customer
experience with, utilization of, and
short-term outcomes of technical
assistance and trainings for diabetes
prevention and management.
• Understandability, ease of use, and
appropriateness of diabetes education
messages, toolkits, programs, and
marketing materials.
• Exploratory assessments of
knowledge, attitudes, behaviors, beliefs,
barriers, and facilitators to uptake and
use of lifestyle change programs for
diabetes type 2 prevention and diabetes
management services and related
innovations, resources, tools, and
materials.
Data collection methods proposed
include, but are not limited to in-depth
individual interviews, cognitive
interviews, intercept interviews, groupbased discussions (including focus
groups and dyads/triads), surveys or
questionnaires, knowledge assessments,
observational assessments, and
implementation and utilization data
reporting. Respondents would include
key audiences and stakeholders of
CDC’s work, including representatives
of state and local DDT-funded
organizations; national, state, and local
DDT partners (not CDC-funded);
providers of type 2 diabetes prevention
and diabetes management programs and
services, including lifestyle coaches,
diabetes care and educations specialists,
healthcare and other providers; heath/
medical and community-based
organizations implementing programs
and services related to type 2 diabetes
prevention and diabetes management;
people with—and at risk for—diabetes
or with prediabetes; family, friends, and
caregivers of people with—and at risk
for—diabetes or with prediabetes.
As the methods for data collection
and audiences may vary with each
request submitted under this proposed
generic clearance, for each data
collection request unique instruments
(e.g., surveys, interview guides) will be
developed to address the specific topics
that information will be collected on.
Questions to be asked may focus, for
example, on collecting data on the
audiences’ needs and on the reach,
uptake, use, customer experience and
satisfaction with DDT’s services,
products, and programs. Such
information will enable DDT to identify
ways to improve its services, products,
and programs to better meet its
audiences’ needs and achieve its
mission of supporting the prevention of
diabetes and reducing diabetes-related
complications and disparities across the
United States.
CDC requests a three-year approval for
6,000 burden hours for this proposed
Generic package. Based on projections,
the estimated annualized hourly burden
anticipated for all data collection
methods would total 2,000 hours and
include eight to ten data collection
activities over the course of a year.
There is no cost to the respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
lotter on DSK11XQN23PROD with NOTICES1
Type of respondents
Data collection methods
Representatives of state and local DDT-funded organizations; national, state, and local DDT partners (not CDCfunded); providers of type 2 diabetes prevention and diabetes management programs and services; heath/medical
and community-based organizations implementing programs and services related to type 2 diabetes prevention
and diabetes management; people with—and at risk for—
diabetes or with prediabetes; family, friends, and caregivers of people with—and at risk for—diabetes or with
prediabetes.
VerDate Sep<11>2014
17:17 Nov 15, 2024
Jkt 265001
PO 00000
Frm 00042
Interviews; surveys or questionnaires; knowledge assessments; motivation assessments, observational
assessments; implementation and utilization data reporting.
Fmt 4703
Sfmt 4703
Number of
respondents
across
methods
Number
responses per
respondent
Average
burden per
response
4,000
1
30/60
E:\FR\FM\18NON1.SGM
18NON1
Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–26780 Filed 11–15–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10398 #85]
Medicaid and Children’s Health
Insurance Program (CHIP) Generic
Information Collection Activities:
Proposed Collection; Comment
Request
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
On May 28, 2010, the Office
of Management and Budget (OMB)
issued Paperwork Reduction Act (PRA)
guidance related to the ‘‘generic’’
clearance process. Generally, this is an
expedited process by which agencies
may obtain OMB’s approval of
collection of information requests that
are ‘‘usually voluntary, low-burden, and
uncontroversial collections,’’ do not
raise any substantive or policy issues,
and do not require policy or
methodological review. The process
requires the submission of an
overarching plan that defines the scope
of the individual collections that would
fall under its umbrella. This Federal
Register notice seeks public comment
on one or more of our collection of
information requests that we believe are
generic and fall within the scope of the
umbrella. Interested persons are invited
to submit comments regarding our
burden estimates or any other aspect of
this collection of information,
including: the necessity and utility of
the proposed information collection for
the proper performance of the agency’s
functions, the accuracy of the estimated
burden, ways to enhance the quality,
utility and clarity of the information to
be collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
December 2, 2024.
ADDRESSES: When commenting, please
reference the applicable form number
(CMS–10398 #85) and the OMB control
number (0938–1148). To be assured
consideration, comments and
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:17 Nov 15, 2024
Jkt 265001
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: CMS–10398 #85/OMB
control number: 0938–1148, Room C4–
26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
medicare/regulations-guidance/
legislation/paperwork-reduction-act1995/pra-listing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at 410–786–4669.
SUPPLEMENTARY INFORMATION: Following
is a summary of the use and burden
associated with the subject information
collection(s). More detailed information
can be found in the collection’s
supporting statement and associated
materials (see ADDRESSES).
Generic Information Collection
1. Title of Information Collection: 3.1–
M State Plan Amendment (SPA)
Templates for Eligible Juveniles Who
are Inmates of a Public Institution; Type
of Information Collection Request: New
information collection request
information request; Use: Section 5121
of the Consolidated Appropriation Act
of 2023 (CAA, 2023) creates a new
mandate for states by amending section
1902(a)(84) of the Social Security Act
(the Act) (42 U.S.C. 1396a) to require
states to provide specific screening and
diagnostic services and targeted case
management (including referrals) in the
30 days prior to release from
incarceration, and targeted case
management (TCM) (including referrals)
for at least 30 days post release for
eligible juveniles who are inmates of a
public institution, post adjudication.
The requirements are effective January
1, 2025.
To comply with the amendments
states must submit a Medicaid SPA
attesting that the state has developed an
internal operation plan, and in
accordance with such plan, will provide
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
90705
coverage during the statutory pre- and
post-release period of screening,
diagnostic, and TCM services for
eligible juveniles who are within 30
days of release post adjudication.
States have the option to lift the
Medicaid inmate payment and CHIP
eligibility exclusions and provide
coverage of pre-release Medicaid and
CHIP services (for electing states) and
makes available federal matching funds
for the full breadth of Medicaid and
CHIP benefits to eligible juveniles who
are incarcerated and pending
disposition of charges. States selecting
this state plan option must provide to
eligible juveniles all mandatory and
optional services to which they are
otherwise entitled under the state plan.
During the period when an eligible
juvenile is incarcerated and pending
disposition of charges, this is essentially
a full lifting of the Medicaid inmate
payment exclusion and CHIP eligibility
exclusion. States cannot choose to
provide a limited array of state plan
services under this option. An
operational plan is not required for this
state option.
For states that wish to elect the option
in section 5122 of the CAA, 2023, states
should submit a SPA attesting to CMS
that they are also electing coverage for
any Medicaid or CHIP state plan
services for eligible juveniles pending
disposition of charges to which the
beneficiary would otherwise be entitled,
if not for their incarceration status.
Form Number: CMS–10398 #85 (OMB
control number: 0938–1148); Frequency:
Once and on occasion; Affected Public:
State, Local, or Tribal Governments;
Number of Respondents: 56; Total
Annual Responses: 168; Total Annual
Hours: 4,872. (For policy questions
regarding this collection contact:
Marlana Thieler at 410–786–6274.)
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–26713 Filed 11–15–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–4467]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Prescription Drug
User Fee Program
AGENCY:
Food and Drug Administration,
HHS.
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 89, Number 222 (Monday, November 18, 2024)]
[Notices]
[Pages 90703-90705]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26780]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-25-24HQ]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Division of Diabetes Translation
Programmatic & Participant User Experience Data Collection (DDTDC)'' to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on July 26, 2024 to obtain
comments from the public and affected agencies. CDC received zero
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Division of Diabetes Translation Programmatic & Participant User
Experience Data Collection (DDTDC)--New--National Center for Chronic
Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Division of Diabetes Translation (DDT) plays a crucial role in
helping prevent Type 2 diabetes, reducing diabetes complications and
disability, and reducing diabetes-related disparities across the United
States. DDT accomplishes this by providing education, training,
technical assistance (TA), and engaging in communication/marketing
activities for various key audiences. These customers include national,
state, and local partners, grantees, providers (e.g., lifestyle
coaches, diabetes educators, healthcare providers, health/medical and
community-based organizations), people with prediabetes, diabetes and
their family, friends, and caregivers, and other consumers of DDT
products and programs.
For DDT to be able to efficiently and effectively do this work and
fulfill its mission, it needs to be able to collect information and
feedback from intended audiences in a timely manner and with enough
frequency to ensure DDT can deliver clear, effective, efficient, and
appropriate customer service. This includes, for instance, collecting
data on key audiences' needs and on the reach, uptake, use, customer
experience and satisfaction with DDT's services, products, and related
programs, including its education, training, TA and communications
services and products.
However, in the interest of timely provision of services, DDT often
forgoes the important step of getting input from its key audiences on
the clarity, efficiency, effectiveness, and appropriateness of the
services and resources it develops and provides for them. Skipping this
information collection step, or doing so with less frequency, avoids
the delay involved in the standard OMB review process, but increases
the risk of DDT wasting both time and money developing and providing
education, training, TA, and communication/marketing that will not
achieve the intended objectives and will be unclear, irrelevant, or not
fully meet the needs of DDT's audiences. It can also have other
unintended consequences, such as jeopardizing the credibility of
Federal health officials.
The Division of Diabetes Translation Programmatic & Participant
User Experience Data Collection (DDTDC) will enable DDT to collect the
information they require in a timely manner to:
Provide clear, effective, efficient, appropriate, and
timely education, communication, training, and technical
[[Page 90704]]
assistance to key audiences and other interested groups, including
consumer audiences (e.g., people with prediabetes, diabetes, and their
family, friends, and caregivers), providers (e.g., lifestyle coaches,
diabetes care and education specialists, healthcare and other
providers, health/medical and community-based organizations); and
partners (national, state, and local partners).
Ensure quality and prevent duplication in the development
and dissemination of prevention and health information and program
activities by DDT to consumers, providers, and state and local
partners.
Conduct exploratory/formative assessments to inform DDT's
development of education, communication/marketing, training, and
programmatic materials, tools, and resources to support and improve the
prevention and management of diabetes. For example, identifying key
audiences' knowledge, attitudes, behaviors, motivators, and information
needs.
Assess the impact of programs, messages, educational and
training materials among recipients and determine to what extent they
meet relevant service-related DDT objectives and goals.
The following are examples of the areas of focus that the data
collection activities under this generic information collection
mechanism may include:
Reach, uptake, use, customer experience, and satisfaction
with the CDC-recognized lifestyle change programs for type 2 diabetes
prevention, as well as related outcomes (e.g., participant retention
and recruitment rates).
Satisfaction with CDC-recognized lifestyle change programs
toolkits, such as the Personal Success Tool and Champion toolkits.
Reach, uptake, use, customer experience, and satisfaction
with diabetes education, type 2 prevention, and diabetes management
innovations (such as the Diabetes Self-Management Education and Support
services promotion initiative) and related short-term effects on
knowledge, awareness, practices (such as information seeking), and
outcomes (such as enrollment of people with diabetes or prediabetes).
Reach, uptake, satisfaction, customer experience, and
short-term outcomes of CDC's training and technical assistance
resources (such as a webinar or online toolkit).
Needs assessments for customer experience with,
utilization of, and short-term outcomes of technical assistance and
trainings for diabetes prevention and management.
Understandability, ease of use, and appropriateness of
diabetes education messages, toolkits, programs, and marketing
materials.
Exploratory assessments of knowledge, attitudes,
behaviors, beliefs, barriers, and facilitators to uptake and use of
lifestyle change programs for diabetes type 2 prevention and diabetes
management services and related innovations, resources, tools, and
materials.
Data collection methods proposed include, but are not limited to
in-depth individual interviews, cognitive interviews, intercept
interviews, group-based discussions (including focus groups and dyads/
triads), surveys or questionnaires, knowledge assessments,
observational assessments, and implementation and utilization data
reporting. Respondents would include key audiences and stakeholders of
CDC's work, including representatives of state and local DDT-funded
organizations; national, state, and local DDT partners (not CDC-
funded); providers of type 2 diabetes prevention and diabetes
management programs and services, including lifestyle coaches, diabetes
care and educations specialists, healthcare and other providers; heath/
medical and community-based organizations implementing programs and
services related to type 2 diabetes prevention and diabetes management;
people with--and at risk for--diabetes or with prediabetes; family,
friends, and caregivers of people with--and at risk for--diabetes or
with prediabetes.
As the methods for data collection and audiences may vary with each
request submitted under this proposed generic clearance, for each data
collection request unique instruments (e.g., surveys, interview guides)
will be developed to address the specific topics that information will
be collected on. Questions to be asked may focus, for example, on
collecting data on the audiences' needs and on the reach, uptake, use,
customer experience and satisfaction with DDT's services, products, and
programs. Such information will enable DDT to identify ways to improve
its services, products, and programs to better meet its audiences'
needs and achieve its mission of supporting the prevention of diabetes
and reducing diabetes-related complications and disparities across the
United States.
CDC requests a three-year approval for 6,000 burden hours for this
proposed Generic package. Based on projections, the estimated
annualized hourly burden anticipated for all data collection methods
would total 2,000 hours and include eight to ten data collection
activities over the course of a year. There is no cost to the
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Number
Type of respondents Data collection respondents responses per Average burden
methods across methods respondent per response
----------------------------------------------------------------------------------------------------------------
Representatives of state and local Interviews; surveys or 4,000 1 30/60
DDT-funded organizations; national, questionnaires;
state, and local DDT partners (not knowledge
CDC-funded); providers of type 2 assessments;
diabetes prevention and diabetes motivation
management programs and services; assessments,
heath/medical and community-based observational
organizations implementing programs assessments;
and services related to type 2 implementation and
diabetes prevention and diabetes utilization data
management; people with--and at risk reporting.
for--diabetes or with prediabetes;
family, friends, and caregivers of
people with--and at risk for--
diabetes or with prediabetes.
----------------------------------------------------------------------------------------------------------------
[[Page 90705]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-26780 Filed 11-15-24; 8:45 am]
BILLING CODE 4163-18-P
